Litmus email source
Copy source
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"> <head> <title>Novo Nordisk</title> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml><![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table { border-collapse: collapse; border-spacing: 0; mso-line-height-rule: exactly; mso-margin-bottom-alt: 0; mso-margin-top-alt: 0; mso-table-lspace: 0pt; mso-table-rspace: 0pt;} td {mso-hyphenate: none;} </style> <![endif]--> <!--[if gte mso 9]> <style> sup, sub { font-size: 100% !important; } </style> <![endif]--> <style type="text/css"> @media screen { @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 400; font-display: fallback; src: local('Noto Sans Italic'), local('NotoSans-Italic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0OIpQlx3QUlC5A4PNr4ARCQ_mu72Bi.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold Italic'), local('NotoSans-BoldItalic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0TIpQlx3QUlC5A4PNr4Az5ZuyDzW1IPrie.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 400; font-display: fallback; src: local('Noto Sans'), local('NotoSans'), url('https://fonts.gstatic.com/s/notosans/v9/o-0IIpQlx3QUlC5A4PNr5TRASf6M7Q.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold'), local('NotoSans-Bold'), url('https://fonts.gstatic.com/s/notosans/v9/o-0NIpQlx3QUlC5A4PNjXhFVZNyBx2pqPA.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } } #outlook a { padding: 0; } .ReadMsgBody { width: 100%; } .ExternalClass { width: 100%; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body, table, td, a { -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } table, td { mso-table-lspace: 0pt; mso-table-rspace: 0pt; } img { -ms-interpolation-mode: bicubic; } body { margin: 0; padding: 0; } img { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; } table { border-collapse: collapse !important; } body { height: 100% !important; margin: 0 auto !important; padding: 0; width: 100% !important; } .default-blue-text a { color: #001965; text-decoration: none; } .default-blue-link-text a { color: #025edc; text-decoration: underline; } @media screen and (max-width: 670px) { img.img-responsive { width: 100% !important; height: auto !important; } } @media screen and (max-width: 480px) { .img-mobile-width-240 { width: 240px !important; height: auto !important; } } @media screen and (max-width: 670px) { .max-width-mobile-320 { max-width: 320px !important; } } @media screen and (max-width: 670px) { table.mobile-hide, td.mobile-hide, img.mobile-hide, .mobile-hide { display: none !important; } } @media screen and (max-width: 670px) { div.mobile-only-content { display: block !important; max-height: none !important; max-width: 100% !important; height: auto !important; width: auto !important; visibility: visible !important; } } @media screen and (max-width: 670px) { th.responsive-th { display: block !important; width: 100% !important; } } @media screen and (max-width: 670px) { .email-container { max-width: 610px !important; width: 100% !important; } } @media screen and (max-width: 670px) { .col-30 { width: 100% !important; } .col-40 { width: 100% !important; } .col-80 { width: 100% !important; } .col-130 { width: 100% !important; } .col-180 { width: 100% !important; } .col-280 { width: 100% !important; } .col-320 { width: 100% !important; } .col-365 { width: 100% !important; } .col-405 { width: 100% !important; } } @media screen and (max-width: 670px) { .mfs-11 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 11px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .text-center { text-align: center !important; } } @media screen and (max-width: 670px) { .mpb-15 { padding-bottom: 15px !important; } .mpb-20 { padding-bottom: 20px !important; } .mpt-32 { padding-top: 32px !important; } .mpb-32 { padding-bottom: 32px !important; } } @media screen and (max-width: 670px) { .email-gutter { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-30 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-only { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-15 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-20 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-50 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-100 { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-10 { padding-right: 10px !important; padding-left: 10px !important; } } </style> </head> <body style="background-color: #ffffff;"> <center style="width: 100%"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #ffffff;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top" class="email-gutter-15" style="padding-bottom: 10px; padding-left: 15px; padding-right: 15px; padding-top: 10px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="top"> <!-- Preheader text --> <div style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 12px;">Clinical data across multiple care settings, including surgery.</div> <!-- Preheader filler spaces --> <div style="display: none; max-height: 0; max-width: 0; width: 0; visibility: hidden; overflow: hidden; font-size: 1px; line-height: 0; mso-hide: all;">  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ </div> </td> <td align="right" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4; width: 100px;"><a href="#" target="_blank" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">View online</a></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="email-gutter-mobile-10" style="padding-bottom: 16px; padding-top: 16px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 5px 0 0;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Important Safety Information</a></td> <td align="center" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;"> | </td> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 0 0 5px;"><a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Prescribing Information</a></td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter" style="padding-left: 30px; padding-right: 30px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/novoseven-logo.png" width="320" height="90" border="0" alt="NovoSeven RT Coagulation Factor VIIa (Recombinant) logo." class="img-mobile-width-240" style="display: inline-block;"></a></td> </tr> <tr> <td align="center" class="email-gutter-20" style="padding-bottom: 20px; padding-left: 20px; padding-right: 20px; padding-top: 12px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: normal; line-height: 18px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is indicated for: Treatment of bleeding episodes and perioperative management in adults and children with congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" style="padding-top: 28px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <th align="center" valign="top" class="mobile-hide col-280" style="width: 280px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/main-image-desktop.jpg" class="mobile-hide" width="280" height="260" border="0" alt="Image of man with bruising on his torso" style="display: block;"></th> <th class="mobile-hide col-40" style="width: 40px;"> </th> <th align="center" valign="top" class="responsive-th col-320" style="font-weight: normal; width: 320px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="email-gutter-mobile-only text-center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 26px; font-weight: normal; line-height: 32px; padding-bottom: 16px; padding-left: 0; padding-right: 0;"><b>NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT is the only bypassing agent FDA-approved for acquired hemophilia,<sup style="font-size: 60%; line-height: 1;">1,2</sup></b> a spontaneous, rare, and potentially fatal disease<sup style="font-size: 60%; line-height: 1;">3</sup></td> </tr> <tr> <td align="left" class="mobile-hide" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;">Model is used for illustrative purposes only.</td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/main-image-mobile.jpg" width="340" height="260" alt="Image of man with bruising on his torso" class="img-responsive" style="display: block; max-width: 340px;"> </div> <!--<![endif]--> </th> <th class="mobile-hide col-30" style="width: 30px;"> </th> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="background-color: #E7EDF7; padding-bottom: 40px; padding-left: 30px; padding-right: 30px; padding-top: 36px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 20px; font-weight: bold; line-height: 24px; padding-bottom: 24px;">Effectively control bleeds in acquired hemophilia</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" align="left" class="col-365" style="float: left; width: 365px;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%" class="max-width-mobile-320"> <tr> <td align="center" width="140" style="width: 140px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 16px; padding-bottom: 8px;">First-line<br>treatment<sup style="font-size: 70%; line-height: 1;">4,a</sup></td> </tr> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/graphic-95-percent.png" width="120" height="120" border="0" alt="Image of efficacy percentage graphic" style="display: block;"></td> </tr> </table> </td> <td> </td> <td align="center" width="140" style="width: 140px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 16px; padding-bottom: 8px;">Salvage<br>therapy<sup style="font-size: 70%; line-height: 1;">4,a</sup></td> </tr> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/graphic-80-percent.png" width="120" height="120" border="0" alt="Image of efficacy percentage graphic" style="display: block;"></td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" align="right" class="col-180" style="float: right; width: 180px;"> <tr> <th align="center" class="col-180 responsive-th" style="font-weight: normal; width: 180px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="mpt-32" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 16px; padding-bottom: 8px;">Effectiveness in surgeries/procedures<sup style="font-size: 70%; line-height: 1;">1,4,a</sup></td> </tr> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/graphic-86-percent.png" width="120" height="120" border="0" alt="Image of efficacy percentage graphic" style="display: block;"></td> </tr> </table> </th> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-bottom: 28px; padding-top: 28px;"><sup style="font-size: 70%; line-height: 1;">a</sup>Data were extracted from a review of experiences with rFVIIa for the treatment for acquired hemophilia in compassionate-use programs, the Hemophilia and Thrombosis Research Society registry, and independently published reports. The percentage of effectiveness noted includes episodes that were evaluated as effective or partially effective. “Ineffective” treatment was determined by the inability to stop the bleeding episode or by the physician describing treatment as not effective. This pertains to 103 bleeding episodes (first-line treatment) and 73 bleeding episodes (salvage therapy) in 139 patients for which efficacy data were available. Bleed protection during surgery data related to 57 surgical bleeding episodes.<sup style="font-size: 70%; line-height: 1;">4</sup></td> </tr> <tr> <td align="center"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt/efficacy-safety/acquired-hemophilia.html" target="_blank" style="background-color: #FF0000; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #FF0000;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:160%;" hidden> </i><span style="mso-text-raise:80%;"><![endif]-->See the data<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" bgcolor="#ffffff" style="background: #ffffff; padding-left: 30px; padding-right: 30px; padding-top: 28px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px;">Scroll down to learn more</td> </tr> <tr> <td align="center" style="padding-bottom: 16px; padding-top: 12px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/arrow.png" width="60" height="40" border="0" alt style="display: block;"> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter mpb-20" style="padding-bottom: 28px; padding-left: 30px; padding-right: 30px; padding-top: 28px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;"> Important Safety Information</td> </tr> <tr> <td align="center" style="padding: 2px; background-color: #001965;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="border: 2px solid #ffffff; background-color: #ffffff;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="background-color: #ffffff; padding-bottom: 20px; padding-left: 14px; padding-right: 14px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="mpb-15" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px; padding-bottom: 10px;">WARNING: THROMBOSIS</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Serious arterial and venous thrombotic events following administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT have been reported </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px; padding-top: 25px;">Warnings and Precautions</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or scroll below for additional Important Safety Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="email-gutter-20 mpt-32" style="background-color: #E7EDF7; padding-bottom: 44px; padding-left: 20px; padding-right: 20px; padding-top: 44px;"> <table border="0" cellpadding="0" cellspacing="0" align="right" class="col-405" style="float: right; width: 405px;"> <tr> <td align="center" class="mpb-32"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: bold; line-height: 26px; padding-bottom: 20px;">Established safety profile</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 22px; padding-bottom: 12px;">Studies show a low rate of thrombotic events</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 16px;">Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.<sup style="font-size: 70%; line-height: 1;">1</sup> Thrombotic adverse reactions in pivotal clinical trials occurred in 4% of patients with acquired hemophilia.<sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 20px; padding-bottom: 12px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #025EDC; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: none;">See Important Safety Information, including Boxed Warning</a>.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" align="left" class="col-130" style="float: left; width: 130px;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 12px;"><b>Data from clinical trials</b><sup style="font-size: 70%; line-height: 1;">1</sup></td> </tr> <tr> <td align="center"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/graphic-4-percent.png" width="120" height="120" border="0" alt style="display: block;"></td> </tr> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 16px; padding-top: 12px;">Occurrence of thrombotic events</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 16px; padding-left: 30px; padding-right: 30px; padding-top: 16px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="background-color: #f7f6f5;"> <tr> <td align="center" class="email-gutter-50" style="padding-bottom: 24px; padding-left: 50px; padding-right: 50px; padding-top: 24px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 22px;">To learn more right away, <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/resources/novonordisk-representative.html" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">request a call with your Rare Blood Institutional Account Manager</a>.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #001965"> <tr> <td align="center" valign="top" class="email-gutter-100" style="padding-bottom: 40px; padding-left: 100px; padding-right: 100px; padding-top: 50px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 26px; font-weight: bold; line-height: 30px; padding-bottom: 34px;">Have you created an account on novoMEDLINK™?</td> </tr> <tr> <td align="center" style="padding-bottom: 26px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/icon-account.png" width="110" height="100" border="0" alt style="display: block;"></td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 20px; padding-left: 30px; padding-right: 30px;"><b>Keep up</b> with important information about treatments for rare bleeding disorders.</td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 20px; padding-left: 30px; padding-right: 30px;"><b>Receive</b> the latest news about rare bleeding disorders from Novo Nordisk.</td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 20px; padding-left: 30px; padding-right: 30px;"><b>Download</b>, order, and share educational materials for you and your patients.</td> </tr> <tr> <td align="center" style="padding-bottom: 20px; padding-top: 20px;"><a href="https://www.novomedlink.com/account/create.html" target="_blank" style="background-color: #001965; border: 2px solid #ffffff; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #001965;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Create Your Account<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <!-- ISI --> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 24px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"><table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;">Indications and Usage</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; padding-bottom: 15px;"> NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for: </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 20px; padding-top: 10px;">Important Safety Information (cont’d)</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Warnings and Precautions </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Adverse Reactions</td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Drug Interactions</td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Thrombosis may occur if NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT is administered concomitantly with Coagulation Factor XIII </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> for Prescribing Information, including Boxed Warning.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="left" class="email-gutter" style="padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 8px;"><b>References:</b></td> </tr> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="20" valign="top" align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">1.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.</td> </tr> <tr> <td width="20" valign="top" align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">2.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">OBIZUR [package insert]. Westlake Village, CA: Baxalta US Inc; 2024.</td> </tr> <tr> <td width="20" valign="top" align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">3.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Radinsky LW, Sivan M, Lubetsky A et al. Acquired hemophilia - a case series and review. <i>J Clin Med</i>. 2025;14(5): 1597.</td> </tr> <tr> <td width="20" valign="top" align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">4.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. <i>Haemophilia</i>. 2007;13(5):451-461.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="border-top: 1px solid #979797"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-style: italic; font-weight: bold; line-height: 22px; padding-bottom: 24px; padding-top: 24px;">Please click on the link to see WAC pricing for the product mentioned above: <a href="https://www.novopricing.com/novosevenrt.html" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;" target="_blank">Product Pricing</a>.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-link-text">Please do not respond to this email. If you would like to contact us, please <a href="https://www.novonordisk-us.com/contact-us.html" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or call <span class="default-blue-link-text" style="white-space: nowrap;">1-800-727-6500</span>.</span></td> </tr> </table> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 20px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="bottom" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> is a registered trademark of Novo Nordisk Health Care AG.<br>novoMEDLINK™ is a trademark of Novo Nordisk A/S.<br>Novo Nordisk is a registered trademark of Novo Nordisk A/S.<br>All other trademarks, registered or unregistered, are the property of their respective owners.<br>© 2026 Novo Nordisk All rights reserved. <span style="white-space: nowrap;">US26NSVN00013</span> <span style="white-space: nowrap;">July 2026</span></span></td> <td align="right" valign="bottom" class="col-80 mobile-hide" style="width: 80px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" style="padding-top: 20px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-hsp-ah-overview-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </center> </body> </html>